Rossari Biotech Ltd (ROSSARI) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management guides for a full-year EBITDA margin of around 12%, with meaningful improvement expected only next year as higher-margin pharma and aroma businesses scale up.
- The Saudi Arabia greenfield project is proceeding cautiously, with land now leased; a detailed capex and timeline will be finalized over the next 8-12 months.
- Critical Ethylene Oxide supply constraints are expected to ease only in Q1 FY28 after the supplier's expansion, which is key to unlocking new capacity utilization.
Performance Overview
- Achieved highest-ever quarterly revenue and EBITDA, driven by broad-based growth across all three business divisions.
- Despite a dynamic external environment with volatile raw material prices and geopolitical pressures, the company maintained stable gross margins and improved EBITDA margins sequentially.
- Export revenues showed strong acceleration, contributing 31% to total revenues, with significant growth in both HPPC and Textile segments.
- The balance sheet strengthened with a reduction in gross borrowings by Rs. 46 crore in H1 and a significant improvement in working capital days from 97 to 86.
- Strategic initiatives are progressing, including the ramp-up of the Thailand facility, portfolio rationalization in the B2C business, and initial steps for a new facility in Saudi Arabia.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.